BP_6
Member
I was thinking about this. With tirzepatide already selling so well and being so successful, why is the exact same company putting the resources into retatrutide? I can see all the other companies developing their own GLP versions, but I find it odd that Ely Lilly is putting in the development cost when they already have a very successful product.
Is it going to be marketed differently for a different purpose to a different customer? Like maybe people with MASH vs just people trying to lose weight? Just one of those things that you think about at night and it keeps you up. At least the way my brain works.
Is it going to be marketed differently for a different purpose to a different customer? Like maybe people with MASH vs just people trying to lose weight? Just one of those things that you think about at night and it keeps you up. At least the way my brain works.
